Abstract

Tuberkulosis merupakan masalah yang serius di masyarakat. Pada tahun 2010, World Health Organization mencatat jumlah penderita tuberkulosis di Indonesia menurun ke posisi empat dengan meningkatnya keberhasilan pengobatan obat antituberkulosis (OAT). Namun, pemberian OAT jangka panjang dapat menyebabkan efek samping ototoksik berupa gangguan pendengaran dan keseimbangan. Penelitian ini dilakukan untuk mengetahui efek ototoksik pada penderita tuberkulosis paru dengan pemberian OAT di RSUP H. Adam Malik Medan. Penelitian ini bersifat deskriptif dengan pendekatan potong lintang. Analisis univariat dilakukan dengan tabel frekuensi distribusi sedangkan analisis bivariat dilakukan dengan menggunakan uji t dan Fisher’s exact test. Didapatkan 35 penderita tuberkulosis yang memenuhi kriteria inklusi, 22 orang dengan pengobatan tuberkulosis kategori 1 dan 13 orang tuberkulosis kategori 2. Dilakukan pemeriksaan audiometri nada murni dan tes keseimbangan. Tiga orang (33,3%) penderita tuberkulosis kategori 1 dan 6 orang (66,7%) penderita tuberkulosis kategori 2 mengalami gangguan pendengaran (p < 0,05). Hasil tes keseimbangan menunjukkan perbedaan yang signifikan yaitu 7 orang (100%) tuberkulosis kategori 2 dengan positif tes Romberg dan 11 orang (100%) tuberkulosis kategori 2 positif tes tandem Romberg. Gangguan pendengaran dan keseimbangan pada penderita tuberkulosis paru dengan OAT ditemukan lebih tinggi pada kategori 2 dibandingkan dengan kategori 1 dengan perbedaan yang signifikan. Tuberculosis remains a serious problem in the community. In 2010, World Health Organization report that Indonesia’s ranking decrease to fourth position due to success of antituberculosis treatment. But the long term administration of antituberculosis treatment may cause ototoxic effect like hearing and balance impairment. The aim of this study was to describe ototoxic effect of subjects who were given tuberculosis treatment in H. Adam Artikel Penelitian Gangguan Pendengaran dan Keseimbangan pada Penderita Tuberkulosis yang Mendapat Pengobatan Antituberkulosis Kategori 1 dan 2 Hearing and Balance Impairment in Tuberculosis Patient with Category 1st and 2nd Antituberculosis Treatment Indri Adriztina* Adlin Adnan* Siti Hajar Haryuna* Parluhutan Siagian** Sorimuda Sarumpaet*** 430 Malik General Hospital. This is a descriptive study with cross sectional approach. Univariat analysis was done by frequency distribution table, meanwhile bivariat analysis was done by t-test and Fisher’s exact test. Thirty five pulmonary tuberculosis patients met the inclusion criteria. Twenty two patients with 1st category, and 13 patients with 2nd category tuberculosis treatment. Pure tone audiometric and balance examination was evaluated. Three patients (33.3%) of 1st category tuberculosis and 6 (66.7%) patients of 2nd category tuberculosis have hearing loss with significant difference (p<0.05). Balance test showed 7 people (100%) of 2nd category tuberculosis having positive Romberg test and 11 people (100%) of 2nd category tuberculosis having positive tandem Romberg test. Hearing and balance impairment found higher in patients with 2nd category antituberculosis treatment with significantly different.

References

1. Vasconcelos KA, Kritski Al, Netto AR, Frota S. Audiometric evaluation of patients treated for pulmonary tuberculosis. Jornal Brasileiro de Pneumologia. 2012; 38(1): 81-87. 2. Aditama TY, Kamso S, Basri C, Surya A. Pedoman nasional penanggulangan tuberkulosis. Edisi 2. Jakarta: Departemen Kesehatan Republik Indonesia; 2007. 3. World Health Organization. Global tuberculosis control : WHO Report 2011. France: WHO Press; 2011. WHO/HTM/TB/2011.16. 4. Soemantri S, Ariawan I. Analisis lanjut survei prevalensi tuberkulosis 2004 investigasi faktor lingkungan dan faktor resiko tuberkulosis Indonesia. Jakarta: Badan Penelitian dan Pengembangan Kesehatan, Departemen KesehatanRepublik Indonesia dan WHO Indonesia; 2004. 5. Rasmin M, Yunus F, Priyanti ZS, Melintira I, Puspitorini D, Rahayu S, dkk. Profil penderita tuberkulosis paru di RS Persahabatan Januari- Juli 2005. Jurnal Respirologi Indonesia. 2006; 27 (1): 402-8. 6. Lima MLLT, Lessa F, Santos AMA, Medeiros Z. Hearing impairment in patients with tuberculosis from northeast brazil. Revista do Instituto de Medicina Tropical de São Paolo. 2006; 48 (2): 99-102. 7. Ahmed RM, Hannigan IP, Chan RC, Halmagyi GM. Gentamicin ototoxicity: a 23-year selected case series of 103 patients. The Medical Journal of Australia. 2012; 196: 701-4. 8. Altiparmak MR, Pamuk ON, Pamuk GE, Ataman R, Serdengecti K. Is isoniazid ototoxicity in patients undergoing hemodialysis?. Nephron Journal. 2002; 92: 478-80 9. Yerdelen D, Tan M. Ototoxicity probably due to isoniazis in a patient undergoing hemodialysis. Journal of Neurological Sciences. 2008; 25 (14): 51-4. 10. Katijah KS, Anniah M, Precious MN. Ototoxic effects of tuberculosis treatment: how aware are patients. African Journal of Pharmacy and Pharmacology. 2009; 3 (8): 391-9. 11. Menzies D, Jahdali HA, Otaibi BA. Recent developments in treatment of latent tuberculosis infection. The Indian Journal of Medical Research. 2011; 133 (3): 257-66. 12. Donald PR, Marais BJ, Barry CE. Age and the epidemiology and pathogenesis of tuberculosis. The Lancet. 2010; 375: 1906-20. 13. Borgdorff MW, Nagelkerke NJD, Dye C, Nunn P. Gender and tuberculosis: a comparison of prevalence surveys with notification data to explore sex differences in case detection. The International Journal of Tuberculosis and Lung Disease. 2000; 4 (2): 123-32. 14. Diwan VK, Thorson A. Sex, gender and tuberculosis. The Lancet. 1999; 353:1000-1. 15. Rybak LP, Talaska AE, Schacht J. Drug-Induced Hearing Loss. In: Fay, R.R., Popper, A.N. (eds) Auditory Trauma Protection and Repair. 1st ed. New York: Springer; 2008. p. 219-54. 16. Water TRVD, Staecker H. Otolaryngology, basic science and clinical review. 1st Ed. New York: Medical Publisher, inc; 2007. p. 129-30 17. Gulbay BE, Gurkan OU, Yildiz OA, Onen ZP, Erkekol FO, Baccioglu A, et al. Side effect due to primary antituberculosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosis. Respiratory Medicine. 2006; 100 (10): 1834-942. 18. East JE, Foweraker JE, Murgatroyd FD. Gentamicin induced ototoxicity during treatment of enterococcal endocarditis: resolution with substitution by netilmicin. Heart. 2005; 91: 1-2. 19. Javadi MR, Abtahi B, Gholami K, Moghadam BS, Tabarsi P, Salamzadeh J. The Incidence of Amikacin ototoxicity in multidrug-resistant tuberculosis patients. Iranian Journal of Pharmaceutical Research. 2011; 10(4): 5-911 20. Peloquin CA, Berning SE, Nitta AT, Simone PM, Goble M, Huitt GA, et al. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of Mycobacterial disease. Clinical Infections Disease: an official publication of the Infectios Disease. 2004; 38: 1538-44. 21. Filho PA, Maranhao ET, Silva MM, Lima MA. Rethinking the neurological examination I. Arquivos de Neuro-psiquiatria. 2011; 69 (6): 954- 8. 22. Cureoglu S, Schachern PA, Paparella MM. Effect of parenteral aminoglycoside administration on dark cells in the crista ampullaris. Archives of Otolaryngology-head & Neck Surgery. 2003; 129: 626-8. 23. Duggal P, Malay S. Audiologic monitoring of multi-drug resistant tuberculosis patients on aminoglycoside treatment with long term followup. BMC Ear, Nose and Throat Disorder. 2007; 7 (5): 1-7. 24. American Academy of Audiology [homepage on the internet]. American Academy of Audiology Position Statement and Clinical Practice Guidelines: Ototoxicity Monitoring. United State of America: Am Academy of Audiology; 2009 (updates 2009 Oct; cited 2012 Feb 02). Available from: http://www.audiology.org. 25. Sha SH, Taylor R, Forge A, Schacht J. Differential vulnerability of basal and apical hair cell is based on intrinsic susceptibility to free radical. Hear Research. 2001; 155: 1-8.

Download

Share

COinS